Skip to Content

Cardura XL Approval History

FDA Approved: Yes (First approved February 22, 2005)
Brand name: Cardura XL
Generic name: doxazosin mesylate
Dosage form: Extended Release Tablets
Company: Pfizer Inc.
Treatment for: Benign Prostatic Hyperplasia

Cardura XL is an extended release formulation providing a controlled release of doxazosin over a 24-hour period. Cardura XL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Cardura XL is not indicated for the treatment of hypertension.

Development History and FDA Approval Process for Cardura XL

DateArticle
Feb 22, 2005Approval Cardura XL Pfizer Inc. - Treatment for Benign Prostatic Hyperplasia (BPH)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide